doi: 10.1111/hae.13943.
Epub 2020 Mar 6.
Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres
Affiliations
- PMID: 32142196
- DOI: 10.1111/hae.13943
Item in Clipboard
Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres
Haemophilia.
2020 May.
No abstract available
Similar articles
-
Real-life experience in switching to new extended half-life products at European haemophilia centres.Haemophilia. 2019 Nov;25(6):946-952. doi: 10.1111/hae.13834. Epub 2019 Aug 16. Haemophilia. 2019. PMID: 31418967
-
A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B.Haemophilia. 2020 Mar;26(2):278-281. doi: 10.1111/hae.13936. Epub 2020 Feb 21. Haemophilia. 2020. PMID: 32083769
-
Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.Haemophilia. 2015 Nov;21(6):784-90. doi: 10.1111/hae.12721. Epub 2015 May 20. Haemophilia. 2015. PMID: 25990590 Free PMC article. Clinical Trial.
-
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.Thromb Haemost. 2017 Jun 2;117(6):1023-1030. doi: 10.1160/TH16-12-0942. Epub 2017 Mar 30. Thromb Haemost. 2017. PMID: 28357444 Review.
-
Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.Br J Haematol. 2015 Jun;169(6):768-76. doi: 10.1111/bjh.13360. Epub 2015 Mar 7. Br J Haematol. 2015. PMID: 25754016 Review.
Cited by
-
Perceptions about the efficacy of extended half-life (EHL) factor products in persons with haemophilia (PWH): A national survey of haemophilia providers from haemophilia treatment centres (HTCs) in the United States.Haemophilia. 2021 Nov;27(6):e780-e783. doi: 10.1111/hae.14427. Epub 2021 Sep 30. Haemophilia. 2021. PMID: 34592042 Free PMC article. No abstract available.
-
The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors.J Manag Care Spec Pharm. 2021 May;27(5):667-673. doi: 10.18553/jmcp.2021.27.5.667. J Manag Care Spec Pharm. 2021. PMID: 33908280 Free PMC article.
-
IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data.J Clin Med. 2022 Feb 18;11(4):1071. doi: 10.3390/jcm11041071. J Clin Med. 2022. PMID: 35207344 Free PMC article. Review.
-
Extravascular factor IX after gene therapy in hemophilia B, does it matter?Res Pract Thromb Haemost. 2025 Mar 6;9(2):102723. doi: 10.1016/j.rpth.2025.102723. eCollection 2025 Feb. Res Pract Thromb Haemost. 2025. PMID: 40236283 Free PMC article.
-
Optimal trough levels in haemophilia B: Raising expectations.Haemophilia. 2020 Nov;26(6):e334-e336. doi: 10.1111/hae.14098. Epub 2020 Aug 25. Haemophilia. 2020. PMID: 32842166 Free PMC article. No abstract available.
References
REFERENCES
-
- Gui T, Lin HF, Jin DY, et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood. 2002;100(1):153-158.
-
- Stern DM, Knitter G, Kisiel W, Nawroth PP. In vivo evidence of intravascular binding sites for coagulation factor IX. Br J Haematol. 1987;66(2):227-232.
-
- Cheung WF, van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA. 1996;93:11068-11073.
-
- Gui T, Reheman A, Ni H, et al. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost. 2009;7(11):1843-1851.
-
- Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with aemophilia B. Blood. 2011;118:2695-2701.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
